Search research articles
Contact Us
Filters
Showing results (121-130 of 150) with videos related to
Page
of 15
Sort By:
HIV Medicine
|
May 9, 2022
Bictegravir/emtricitabine/tenofovir alafenamide in older individuals with HIV: Results of a 96-week, phase 3b, open-label, switch trial in virologically suppressed people ≥65 years of age
Franco Maggiolo, Giuliano Rizzardini, Jean-Michel Molina, et al.
The Journal of Antimicrobial Chemotherapy
|
April 17, 2007
CD4+ T cell evolution and predictors of its trend before and after tenofovir/didanosine backbone in the presence of sustained undetectable HIV plasma viral load
Carlo Torti, Giuseppe Lapadula, Pablo Barreiro, et al.
Open Forum Infectious Diseases
|
July 7, 2018
Impact of the M184V Resistance Mutation on Virological Efficacy and Durability of Lamivudine-Based Dual Antiretroviral Regimens as Maintenance Therapy in Individuals With Suppressed HIV-1 RNA: A Cohort Study
Roberta Gagliardini, Arturo Ciccullo, Alberto Borghetti, et al.
AIDS Research and Human Retroviruses
|
June 22, 2023
Factors Associated with Low-Level Viremia in People Living with HIV in the Italian Antiviral Response Cohort Analysis Cohort: A Case-Control Study
Francesca Lombardi, Elena Bruzzesi, Yagai Romeo Bouba, et al.
Medicine
|
July 22, 2016
Liver fibrosis progression and clinical outcomes are intertwined: role of CD4+ T-cell count and NRTI exposure from a large cohort of HIV/HCV-coinfected patients with detectable HCV-RNA: A MASTER cohort study
Emanuele Focà, Massimiliano Fabbiani, Mattia Prosperi, et al.
Current HIV Research
|
July 16, 2009
Clinical validation and applicability of different tipranavir/ritonavir genotypic scores in HIV-1 protease inhibitor-experienced patients
Annalisa Saracino, Laura Monno, Alessandra Tartaglia, et al.
Clinical Infectious Diseases : an Official Publication of the Infectious Diseases Society of America
|
March 2, 2022
Efficacy and Safety of Switching to the 2-Drug Regimen Dolutegravir/Lamivudine Versus Continuing a 3- or 4-Drug Regimen for Maintaining Virologic Suppression in Adults Living With Human Immunodeficiency Virus 1 (HIV-1): Week 48 Results From the Phase 3, Noninferiority SALSA Randomized Trial
Josep M Llibre, Carlos Brites, Chien-Yu Cheng, et al.
International Journal of Antimicrobial Agents
|
January 12, 2024
Characterization and outcomes of difficult-to-treat patients starting modern first-line ART regimens: Data from the ICONA cohort
Roberta Gagliardini, Alessandro Tavelli, Stefano Rusconi, et al.
Plos One
|
September 16, 2016
Risk of Chronic Kidney Disease among Patients Developing Mild Renal Impairment during Tenofovir-Containing Antiretroviral Treatment
Giuseppe Lapadula, Davide Paolo Bernasconi, Salvatore Casari, et al.
The Journal of Infectious Diseases
|
January 22, 2014
Dolutegravir in antiretroviral-experienced patients with raltegravir- and/or elvitegravir-resistant HIV-1: 24-week results of the phase III VIKING-3 study
Antonella Castagna, Franco Maggiolo, Giovanni Penco, et al.
Page
of 15
Search research articles
Search
Showing results (121-130 of 150) with videos related to
Sort By:
Page
of 15
HIV Medicine
|
May 9, 2022
Bictegravir/emtricitabine/tenofovir alafenamide in older individuals with HIV: Results of a 96-week, phase 3b, open-label, switch trial in virologically suppressed people ≥65 years of age
Franco Maggiolo, Giuliano Rizzardini, Jean-Michel Molina, et al.
The Journal of Antimicrobial Chemotherapy
|
April 17, 2007
CD4+ T cell evolution and predictors of its trend before and after tenofovir/didanosine backbone in the presence of sustained undetectable HIV plasma viral load
Carlo Torti, Giuseppe Lapadula, Pablo Barreiro, et al.
Open Forum Infectious Diseases
|
July 7, 2018
Impact of the M184V Resistance Mutation on Virological Efficacy and Durability of Lamivudine-Based Dual Antiretroviral Regimens as Maintenance Therapy in Individuals With Suppressed HIV-1 RNA: A Cohort Study
Roberta Gagliardini, Arturo Ciccullo, Alberto Borghetti, et al.
AIDS Research and Human Retroviruses
|
June 22, 2023
Factors Associated with Low-Level Viremia in People Living with HIV in the Italian Antiviral Response Cohort Analysis Cohort: A Case-Control Study
Francesca Lombardi, Elena Bruzzesi, Yagai Romeo Bouba, et al.
Medicine
|
July 22, 2016
Liver fibrosis progression and clinical outcomes are intertwined: role of CD4+ T-cell count and NRTI exposure from a large cohort of HIV/HCV-coinfected patients with detectable HCV-RNA: A MASTER cohort study
Emanuele Focà, Massimiliano Fabbiani, Mattia Prosperi, et al.
Current HIV Research
|
July 16, 2009
Clinical validation and applicability of different tipranavir/ritonavir genotypic scores in HIV-1 protease inhibitor-experienced patients
Annalisa Saracino, Laura Monno, Alessandra Tartaglia, et al.
Clinical Infectious Diseases : an Official Publication of the Infectious Diseases Society of America
|
March 2, 2022
Efficacy and Safety of Switching to the 2-Drug Regimen Dolutegravir/Lamivudine Versus Continuing a 3- or 4-Drug Regimen for Maintaining Virologic Suppression in Adults Living With Human Immunodeficiency Virus 1 (HIV-1): Week 48 Results From the Phase 3, Noninferiority SALSA Randomized Trial
Josep M Llibre, Carlos Brites, Chien-Yu Cheng, et al.
International Journal of Antimicrobial Agents
|
January 12, 2024
Characterization and outcomes of difficult-to-treat patients starting modern first-line ART regimens: Data from the ICONA cohort
Roberta Gagliardini, Alessandro Tavelli, Stefano Rusconi, et al.
Plos One
|
September 16, 2016
Risk of Chronic Kidney Disease among Patients Developing Mild Renal Impairment during Tenofovir-Containing Antiretroviral Treatment
Giuseppe Lapadula, Davide Paolo Bernasconi, Salvatore Casari, et al.
The Journal of Infectious Diseases
|
January 22, 2014
Dolutegravir in antiretroviral-experienced patients with raltegravir- and/or elvitegravir-resistant HIV-1: 24-week results of the phase III VIKING-3 study
Antonella Castagna, Franco Maggiolo, Giovanni Penco, et al.
Page
of 15